Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimers patients--an open-label trial
International Journal of Geriatric Psychiatry, 04/19/2012Kennelly S et al.
In this open–label trial, among APOE ε4 non–carriers, the authors observed stabilization of cognition and improvement in executive function among treated individuals compared with non–treated individuals. Among APOE ε4 carriers, cognitive stabilization was evident for treated individuals whereas a cognitive decline was observed in non–treated individuals. These findings provide additional evidence for potential therapeutic efficacy of nilvadipine in treating Alzheimer's disease.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.